Clinical Trial Update: Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing whether a single 3 mg evening dose of eszopiclone affects next-day driving ability in adults with primary insomnia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Eszopiclone (eszopiclone)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED